The Rise of Decentralized Trials: How Modern Clinical Research Is Going Remote

Recent Trends in Decentralized Research

Over the past several years, clinical trial sponsors have increasingly adopted decentralized elements—such as remote consent, home health visits, and digital data collection—to reduce the burden on participants. The shift accelerated during the COVID-19 pandemic, when in-person visits became impractical, and has continued as technology and regulatory guidance mature. Many large pharmaceutical companies now run hybrid models that combine centralized sites with at-home or local-laboratory components.

• Use of wearable devices and mobile apps for real-time symptom tracking rose in a majority of late-phase trials.
• Telemedicine consultations replaced some on-site check-ins, particularly for routine assessments.
• Direct-to-patient drug shipment and local phlebotomy services became more common, especially in rare-disease and oncology studies.

Background: Why Decentralization Matters

Traditional clinical trials require participants to travel repeatedly to a central site, often a major academic medical center. This can limit enrollment to people who live nearby, have flexible schedules, or can afford travel costs. Decentralized approaches aim to expand access by bringing research activities closer to where patients live and work.

• Eligible participant pools can broaden, potentially reducing recruitment delays and improving demographic diversity.
• Remote data collection may capture more continuous, real-world information rather than occasional snapshots.
• Regulatory agencies in several regions have issued draft or final guidance on decentralized trial conduct, clarifying expectations for informed consent, data privacy, and site oversight.

User Concerns and Practical Challenges

While decentralization offers convenience, it also raises valid concerns among participants, investigators, and sponsors. Not every population or disease is well-suited to a fully remote model, and gaps remain in technology access and health literacy.

• Reliable internet connectivity and device proficiency vary by age, income, and geographic region, which can exclude certain groups.
• Home-based assessments may not replace specialized imaging, biopsies, or infusion visits that require dedicated equipment or supervision.
• Data security and patient privacy become more complex when information flows across multiple remote devices and local labs.
• Study teams face logistical hurdles in coordinating home health nurses, couriers, and local labs across large areas.

Likely Impact on Clinical Research

The gradual adoption of decentralized methods is reshaping trial design, costs, and timelines. Sponsors report that hybrid models can shorten enrollment windows and reduce screen-failure rates by lowering geographic barriers. However, upfront investment in technology and training can increase, and some site-based infrastructure remains essential.

• Trials with moderate visit frequency and non-invasive endpoints—common in chronic conditions like type 2 diabetes, hypertension, or depression—are most likely to shift toward decentralized models.
• Phase I and early safety studies still typically require closely monitored in-clinic settings.
• Regulators expect sponsors to demonstrate that remote data quality is comparable to site-collected data, especially for primary endpoints.

What to Watch Next

As decentralized approaches mature, several developments will influence how broadly they are adopted and how they affect research participants.

• Standardization of remote data capture platforms: Interoperability between electronic health records, wearables, and trial databases will reduce manual data entry and errors.
• Updated regulatory frameworks: More countries are expected to issue formal guidance on remote consent, direct-to-patient shipment, and cross-jurisdictional telemedicine.
• Long-term retention metrics: It remains to be seen whether remote engagement reduces dropout rates or, conversely, leads to higher loss to follow-up due to less personal contact.
• Cost-benefit analyses: Real-world data on total trial costs per patient for decentralized vs. traditional designs will inform future investment decisions.